Enhancing cancer care with improved checkpoint inhibitors

a focus on PD-1/PD-L1

Authors

  • Vickram A S Department of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai, India. E-mail: vickramas.sse@saveetha.com https://orcid.org/0000-0003-4319-1575
  • Saghya Infant Shofia Department of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai, India https://orcid.org/0000-0001-9077-9297
  • A. Saravaran Department of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai, India https://orcid.org/0000-0002-5420-8662
  • Vidhya Lakshmi Sivakumar Department of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai, India https://orcid.org/0000-0003-3959-2966
  • Packiyam Thamarai Department of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai, India https://orcid.org/0000-0003-3253-6347
  • Manikandan Sivasubramanian Department of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai, India https://orcid.org/0000-0002-3456-2269
  • Shivani Chopra Department of Biosciences, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai - 602105, Tamil Nadu, India https://orcid.org/0000-0002-2871-086X
  • Hitesh Chopra Center for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India https://orcid.org/0000-0001-8867-7603

DOI:

https://doi.org/10.17179/excli2024-7783

Keywords:

checkpoint inhibitors, PD-1, PD-L1, cancer, immunotherapy

Abstract

The emergence of checkpoint inhibitors targeting the PD-1/PD-L1 axis marks a paradigm shift in cancer therapy, offering a novel avenue for enhancing patient outcomes. This review examines the structural and functional dynamics of PD-1 and PD-L1 while exploring the clinical implications of current PD-1/PD-L1 monoclonal antibodies. Highlighting recent advancements, this paper delves into the promising results from combination therapies that present a multifaceted attack on tumor progression. Despite the success observed across various cancer types, challenges such as immune resistance remain. Future considerations are discussed with an emphasis on the need for further clinical studies, aiming to refine and broaden the curative potential of PD-1/PD-L1 inhibitors in oncology. This review postulates that ongoing research and innovative approaches could significantly enhance cancer care, making immunotherapy an even more central strategy in the fight against cancer.

Downloads

Published

2024-10-29

How to Cite

A S, V., Shofia, S. I., Saravaran, A., Sivakumar, V. L., Thamarai, P., Sivasubramanian, M., … Chopra, H. (2024). Enhancing cancer care with improved checkpoint inhibitors: a focus on PD-1/PD-L1. EXCLI Journal, 23, 1303–1326. https://doi.org/10.17179/excli2024-7783

Issue

Vol. 23 (2024)

Section

Review articles

Categories

License

Copyright (c) 2024 Vickram A S, Saghya Infant Shofia, A. Saravaran, Vidhya Lakshmi Sivakumar, Packiyam Thamarai, Manikandan Sivasubramanian, Shivani Chopra, Hitesh Chopra

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).

Most read articles by the same author(s)